A series of acyclic phosphonomethylether nucleosides were synthesized and then evaluated for inhibitory activity against respiratory viruses of clinical significance using CPE inhibition, neutral red uptake and virus yield reduction assays. Of the 20 compounds synthesized, none significantly inhibited influenza A or B viruses or respiratory syncytial virus strains A2, Long or 18537; the selective indices (51) were less than 10. A new compound, G5-2128 (2R, 5R-9-[2,5-dihydro-5-(phosphonomethoxy)-2-furanyl]adenine; D4API), selectively inhibited adenovirus 5 (51)10) as did G5-0577 (9-(3-hydroxy-2-phosphonylmethoxypropyl)-adenine; HPMPA) and G5-0504 [(S)-1-[3-hydroxy-2-(phosphonylmethoxypropyl)]-cytosine; HPMPC]. The 50% effective concentrations (EC so) ranged from 8-100 I1g mL-l and 50% cell inhibitory concentrations (CC so )from 40-1000 I1g ml.", All three compounds were also found to be active against laboratory strains and clinical isolates of adenovirus types 1, 2, 8 and 41 with EC so values ranging from 0.2 to 10 I1g ml,". Two compounds, G5-438 (9-(2-phosphonylmethoxyethyl)guanine, PMEG) and G5-2542 (9-[3-phosphonomethoxy)methoxymethyl]guanine) inhibited parainfluenza virus 3 strain C243, with 51 of 52 and >333, respectively. PMEG also inhibited measles virus strains CC, Halonen and Chicago with EC so values ranging from 0.03-9119 ml,". These data suggest that these compounds should be considered for possible development as therapeutic agents for respiratory virus infections.
Introduction
Acyclic phosphonomethyl ether nucleosides, first described by De Clercq et al (1986) , are a novel class of compounds with interesting biological activities. Two members of this group in the most advanced stages of clinical development are (S)-1-[3-hydroxy-2-(phosphonylmethoxypropyl)]cytosine (HPMPC) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA). HPMPC (cidofovir), which has broad spectrum antiherpesvirus activity (De Clercq, 1993) , has recently been approved for treatment of human cytomegalovirus retinitis in the US and is currently in clinical trials as a topical treatment for herpes simplex virus (HSV). PMEA (1) inhibits herpesviruses and retroviruses in animal models (Tsai et al., 1994) and is being evaluated against clinical human immunodeficiency virus and Epstein-Barr virus infections. This class of compounds also inhibits parasites (Kaminsky et al., 1994) and has anti-proliferative (Otova et al., 1993a,b; Rose et al., 1990) and immunomodulatory (Otova et al., 1994; Calio et al., 1994; Del Gobbo et al., 1991) activity. Inhibitory activity against respiratory viruses has received only scant attention.
In this study, we report on the in vitro inhibitory activity of 20 phosphonates against influenza A and B viruses, adenovirus (Ad), respiratory syncytial virus (RSV), measles virus (MV) and parainfluenza virus 3 (PIV). Some were very specific and potent inhibitors of virus replication.
at 300 MHz and 121.7 MHz, respectively; J values are reported in Hz. Solutions after extractive isolation were dried over MgS0 4 unless otherwise indicated.
9-[[2-lodo-1-[(diethylphosphinyl)methoxy]ethoxy]methyl]adenine 24
To a suspension of 21 (956 mg, 5.0 mmo1) and diethy1 (hydroxymethyl)phosphonate (5.04 g, 30.0 mmo1) in CH 2C12 (20 mL) at OT was added an 1 2 solution (2.54 g, 10.0 mmo1, in 70 mL CH 2C1J The mixture was stirred for 30 min at O'C. The organic phase was washed with saturated NaHC0 3 , 10% NaS 203 and brine, and dried (Na 2S04 ) , concentrated and chromatographed (5% MeOH in CH 2C12 ) to afford 24 (602 mg, 25%) as a white foam: lH NMR (CDC1 3 ) 08.39 (s, IH), 8.05 (s, IH), 5.85 (d, IH,] 10.8),5.70 (d, IH,] 10.8),5.60 (br s, 2H), 4.96 (t, IH,] 5.4), 4.21 (m, 4H), 3.92 (rn, 2H), 3.20 (d, 2H,] 5.1),1.37 (t, 6H,] 6.9); 31p NMR (CDC1 3 ) 020.04.
9-[[2-lodo-1-[(diethylphosphinyl)methoxy]ethoxy]methyl]cytosine 25
This compound was prepared from 22 as described for compound 24 and the mixture was stirred for 1.5 h at room temperature. Mter preparing the organic phase as described above for 24, the residue was chromatographed (10% MeOH in CH 2C12 ) to yield 25 (539 mg, 54%) as a white foam: lH NMR (CDC1 3 ) 08.03 (br s, IH), 7.40 (d, IH,]7.3), 6.97 (br s, IH), 6.03 (d, IH,]7.3), 5.50 (d, IH, J 10.3),5.14 (d, IH,] 10.3),4.96 (t, IH,] 5.1),4.20 (rn, 4H), 3.98 (rn, 2H), 3.24 (d, 2H,] 5.1),1.36 (t, 6H,]7.0).
2-(Acetylamino)-6-[(diphenylcarbamoyl)oxy]-9-[[2-iodo-1-[(diisopropylphosphinyl)methoxy]ethoxy]-methyl]purine 26
This compound was prepared from 23 as described for compound 24 and the mixture was stirred for 1 h. The organic phase was washed with saturated NaHC0 3 , 10% NaS 203 and brine, dried and the residue chromatographed (gradient 2-4% 2-propano1 in CH 2C12 ) to yield 26 (5.6 g, 41%) as a white foam: lH NMR (CDC1) 0 8.61 (br s, IH), 8.45 (s, IH), 7.52-7.20 (m, 10H), 5.85 (d, IH, JI0.5), 5.70 (d, IH,]10.5), 4.97 (t, IH,]5.0), 4.90-4.75 (rn, 2H), 3.96-3.80 (m, 2H), 3.20 (rn, 2H), 2.51 (s, 3H), 1.35 (rn, 12H); 31p NMR (CDC1 3 ) 0 18.1.
9-[[2-Acetoxy-1-[(diethylphosphinyl)methoxy]ethoxy]methyl]adenine 27
To a solution of 24 (401 mg, 0.83 mmol) in DMF (8.3 mL) was added tetraethylammonium acetate (2.16 mg, 8.3 mmo1). The reaction mixture was heated at 60°C for 5 h and the solvent was evaporated. The residue was diluted with CHC1 3 , washed with water and brine, and dried (Na 2S04 ) and evaporated. The residue was chromatographed (10% MeOH in CH 2C12 ) to afford 27 (184 mg, 224 53%) as a white foam: -n NMR (CDC1 3 ) 0 8.37 (s, IH), 8.05 (s, IH), 6.06 (br s, 2H), 5.87 (d, IH,]10.5), 5.71 (d, IH, J 10.5), 5.08 (t, IH, J 5.2), 4.21 (rn, 4H), 4.11 (m, 2H), 3.92 (m, 2H), 1.96 (s, 3H), 1.37 (t, 6H,J 6.9).
9-[[1-[(Diethylphosph inyl)methoxy]ethoxy]methyl]adenine 28
Compound 24 (258 mg, 0.53 mmo1) in MeOH (5.3 mL) was treated with triethylamine (538 mg, 5.3 rnmol) and stirred with 10% Pd/C (258 mg) under H 2 for 1 h. Celite (1 g) was added, the mix stirred for 5 min and filtered. The filtrate was evaporated and the residue chromatographed (5% MeOH in CH 2C12 ) to give 28 (157 mg, 82%), a white foam: lH NMR (CDC1 3 ) 0 8.39 (s, IH), 8.04 (s, IH), 5.78 (d, IH,J 10.8),5.67 (d, IH,] 10.8),5.60 (br s, 2H), 5.03 (t, IH,] 5.3), 4.21 (m, 4H), 3.82 (d, 2H,] 10.2), 1.36 (t, 6H,]7:1), 1.32 (t, 3H,]5.3); 31p NMR (CDC1 3 ) 021.49.
9-[[2-Acetoxy-1-[(diethylphosphinyl)methoxy]ethoxy]methyl]cytosine 29
This compound was prepared from 25 as described for compound 27 and the solution was heated at 60°C for 6 h. The solvent was evaporated and the residue was diluted with CHC1 3 and washed with water and brine, and dried (Na 2SO 4)' The solvent was evaporated and the residue was chromatographed (10% MeOH in CH 2C12 ) to afford 29 (259 mg, 66%) as a white foam: 'H NMR (CDC1 3 ) 07.87 (br s, IH), 7.40 (d, IH,]7.4), 6.94 (br s, IH), 6.05 (d, IH, J7.4), 5.47 (d, IH,]9.8), 5.21 (d, IH,]9.8), 5.11 (t, IH, J 4.9),4.71 (m, 4H), 4.07 (rn, 2H), 3.97 (m 2H), 2.11 (s, 3H),1.37 (t, 6H,]6.7).
2-(Acetylamino)-6-[((diphenylcarbamoyl)oxy)-9-[(2-acetoxy)-1-[(diisopropylphosphinyl)methoxy]ethoxy]-methyl]purine 30
This compound was prepared from 26 as described for compound 27 and the solution was heated at 50°C for 3 h. The solvent was evaporated and the residue was diluted with ethyl acetate and was washed with water and brine, and dried. The residue was purified by chromatography (2.5% MeOH in CH 2C1) to afford 30 (2.2g, 44%) as a white foam: 'H NMR ( 
2-(Acetylamino)-6-[((diphenylcarbamoyl)oxy)-9-[1-[(diisopropylphosphinyl)methoxy]ethoxy]methyl]purine 31
Iodide 26 (0.1 g, 0.32 mmo1) was dissolved in MeOH (5 mL). Triethylamine (0.2 mL, 1.4 mmo1) was added followed by 5% Pd/C (10% w/w). The suspension was stirred under H 2 (1 atmosphere) for 48 h. The reaction mixture was filtered through celite and the filtrate was evaporated. The residue was resuspended in CHzCl z (10 mL), washed with water and brine, dried and evaporated. The crude product was chromatographed (3% MeOH in CHzCl z) to give 31 (40.6 mg, 47%) as a white foam: -n NMR (CDC1 3) 0 8.55 (br s, 1H), 8.16 (s, 1H), 7.5-7.2 (m, 10H), 5.82 (d, 1H, J 11.6),5.62 (d, 1H, J 11.6), 5.05-4.98 (rn, 1H), 4.86-4.70 (rn, 2H), 3.85-3.6 (m, 2H), 2.53 (s, 3H), 1.40-1.24 (rn, 15H); 3ip NMR (CDC1 3) 0 16.2.
9-[[2-Hydroxy-l-(phosphonomethoxy)ethoxy]methyl]adenine disodium salt 12
A solution of27 (146 mg, 0.37 mmol) in CH 3CN (3.8 mL) at O°C was treated with 2,6-lutidine (0.891 mL) and trimethylsilyl bromide (586 mg, 3.8 mmol).The reactionmixture was stirred at room temperature for 18 h. The volatiles were evaporated and the residuewas dissolved in ammonium hydroxide (2 mL), stirred for an additional 30 min and evaporated.The ammonium salt was convertedto the sodium salt by ion exchange (Ag 50W-X8) and precipitated with water/acetone to afford 12 (102 mg, 80%) as a white powder: iH NMR (DzO) 0 8.30 (s,1H), 8.22 (s,1H), 5.82 (ABq, 2H, J12.0), 4.86 (t, 1H,]4.8),3.49-3.71 (m,4H).
9-[[2-Hydroxy-l-(phosphonomethoxy)ethoxy]methyl]guanine ammonium salt 13
To a solution of 30 (980 mg, 1.38 mmol) in MeOH (22 mL) was added ammonium hydroxide (11 mL) and the solution was refluxed for 1.5 h. The solvents were evaporated and the residue was evaporated twice from MeOH. The residue was chromatographed (10% MeOH in CHzCl z) to afford a white solid (500 mg) which was suspended in CH 3CN (10 mL), cooled to OT and treated sequentially with 2,6-lutidine (2.8 mL, 23.8 mmol) and trimethylsilyl bromide (1.6 mL, 11.9 mrnol). Mter stirring for several min at O°C the reaction was warmed to room temperature and stirred for 18 h. To the resulting suspension was added 1.4 M ammonium hydroxide (25 mL) and the solution was evaporated. The residue was dissolved again in 1.4 M ammonium hydroxide (25 mL), evaporated and the solid obtained was slurried in 1:1 acetone:water (30 mL), filtered, and washed with 1:1 acetone:water and acetone, and dried to afford 13 (382 mg, 78%) as a white solid: iH NMR (DzO) 0 7.96 (s, 1H), 5.65 (ABq, 2H,J 11.4),4.86 (t, 1H,J 4.9),3.71 (dd, 1H,] 9.4,12.6),3.61 (dd, 1H,j5.1, 12.3),3.56-3.49 (rn, 2H); 3ip NMR (DzO) 014.3.
9-[[1-(phosphonomethoxy)ethoxy]methyl]adenine ammonium salt 14
To a solution of 29 (146 mg, 0.37 mmol) in DMF (3.7 mL) was added trimethylsilyl bromide (569 mg, 3.7 mmol) at O°C. The reaction mixture was stirred for 3 h at room temperature, ammonium hydroxide (3.8 mL) was Antiviral Chemistry & Chemotherapy 8 (3) Inhibitors of respiratory viruses added and the solution was evaporated. Purification of the residue by C 18 reverse phase HPLC (CH 3CN/water) afforded 14 (82 mg, 83%) as a white solid: -H NMR (DzO) 07.82 (d, 1H,]6.6),6.10 (d, 1H,]6.6),5.39 (ABq, 2H, J 10.0), 4.88 (t, 1H, J 4.8), 3.74 (rn, 2H), 3.63 (m, 2H); 3ip NMR (DzO) 0 15.22.
9-[[2-Hydroxy-l-(phosphonomethoxy)ethoxy]methyl]cytosine ammonium salt 15
To a solution of28 (72 mg, 0.20 mmol), 2,6-lutidine(0.48 mL) and CH 3CN (2.0 mL) was added trimethylsilyl bromide (308 mg, 2.0 mmol) at OT. The reaction mixture was warmed to room temperature and stirred for 18 h. The reaction was evaporated and ammonium hydroxide (2 mL) was added and stirred for additional 5 min. The solvent was evaporated, converted to the sodium salt by ion exchange (Ag 50W-X8) and precipitated with water/ace- 
9-[[1-(Phosphonomethoxy)ethoxy]methyl]guanine disodium salt 16
To a solution of 31 (0.25 g, 0.06 mmol) in MeOH (1 mL) was added ammonium hydroxide (0.5 mL), the solution was heated to 60°C for 3.5 h and the volatiles evaporated. The residue was chromatographed (10% MeOH in CHzCl z) to yield the diisopropyl ester (24.9 mg) which was suspended in CH 3CN, cooled to O°C and treated with 2,6-lutidine (0.23 mL, 2 mmol) followed by trimethylsilyl bromide (0.132 mL, 1 mmol). The reaction was stirred for 5 min at O°C, warmed to room temperature and stirred for 15 h. Volatiles were evaporated, ammonium hydroxide (2 mL) was added and evaporated twice. The residue was purified by C 18 reverse phase HPLC (gradient: 0-30% B; A, 5% CH 3CN in 0.1 M triethylammonium acetate; B, 75% CH 3CN in 0.1 M triethylammonium acetate) and subsequently desalted by C 18 reverse phase HPLC (gradient: 0-100% CH 3CN in water). The ammonium salt was converted to the sodium form by ion exchange (Ag 50W-X8) and evaporated to give 16 (22 mg, 98%), a white solid: -n NMR (DzO) 0 7.95 (s, 1H), 5.61-5.59 (rn, 2H), 5.03-4.99 (m, 1H), 3.66-3.55 (rn, 2H), 1.30 (d, 3H,]5.4); 3ip NMR (DzO) 0 17.4.
Materials and Experimental Procedures: Virology
Cells Embryonic Mrican green monkey kidney cells (MA-104) were obtained from BioWhittaker (Walkersville, Md., USA) and were grown in MEM (Gibco BRL) sup-plemented with 0.1% NaHC0 3 and 9% fetal bovine serum (FBS; Hyclone Laboratories). Human lung carcinoma cells (A-549), bovine embryonic trachea cells (EBTr) and African green monkey kidney cells (CV-1) were from the ATCC and were grown in Dulbecco's MEM (Gibco BRL) with 0.1% NaHC0 3 and 10% FBS. Madin-Darby canine kidney cells (MDCK; ATCC) were grown in MEM with 5% FBS and 0.1% NaHC0 3 . All cells were grown in media without antibiotics and were maintained in a humidified (5% CO 2 , 37°C) incubator.
Viruses
RSV Utah 89 (Utah State Diagnostic Laboratory, Salt Lake City, Utah, USA), strains A2 and Long (subgroup A; ATCC) and 18537 (subgroup B; Lee Biomolecular) and PIV-3 strain C243 (ATCC) were propagated in MA-104 cells. Bovine RSV (strain 375; ATCC) was grown on EBTr cells.
Ad strains adenoid 6 (type 2), adenoid 75 (type 5), Trim (type 8) TAK (type 41) and LJ (type 38) were from the ATCC. Wt 300 (type 5) was kindly provided by TE Shenk (Howard Hughes Medical Institute, Princeton University, Princeton, N.J., USA); strain 13306 (type 8), a 1995 clinical isolate from a paediatric patient with a respiratory infection was a gift of J Bouvin (Hospitale St Justine, Montreal, Canada) and strain Chicago (type 1), a 1995 clinical isolate (Chicago/l) from the tracheal washings of a paediatric patient with disseminated Ad infection was donated by D Johnson (University of Chicago Hospital, Chicago, Ill., USA). All Ad were grown in A549 cells. MV strains Edmonston and CC were obtained from the ATCC; the Halonen and Chicago strains were provided by JS Rota [Centers for Disease Control (CDC), Atlanta, Ga., USA]. All strains were routinely passaged in CV-l cells.
Influenza virus AlNWS/33 (H1Nl) was obtained from KW Cochran (University ofMichigan, Ann Arbor, Mich., USA). AlTexas/36/91 (H1Nl), AlBeijing/32/92 (H3N2) and B/Panama/5/72 were supplied by H Regnery of the Influenza Branch of the CDC. AlNew Jersey/8/76 (H1Nl), AlPort Chalmers/lI73 (H3N2) and B/Hong Kong/5/72 were from the ATCC. Each virus used was from pools prepared in MDCK cells.
For antiviral tests involving Ad, MV, PIV and RSV, the serum was reduced to 2% and the media were supplemented with 50 I-lg mL-1 gentamicin (Sigma). In antiviral assays Inhibitors of respiratory viruses with influenza viruses in MDCK cells, the test medium was MEM with 0.18% NaHC0 3 , 20 units mL-1 trypsin, 2 I-lg mL-1 of EDTA and 50 I-lg mL-1 of gentamicin.
CPE inhibition assay
CPE inhibition assays used in this study were done as described by Sidwell & Huffman (1971) with slight modifications. Test compounds at varying concentrations and virus at a multiplicity of infection (rn.o.i.) of 0.001 were added to near-confluent cell monolayers and incubated at 3TC until the cells in the control wells showed complete virus CPE as observed by light microscopy (usually 3-5 days). Each concentration of drug was assayed for virus inhibition in quadruplicate and for cytotoxicity in duplicate. Four wells were set aside as uninfected, untreated cell controls per test and four wells per test received virus only and represented positive controls for virus replication. This format allowed two compounds to be evaluated for antiviral activity per 96-well plate. For all CPE-based assays, the 50% effective concentration (EC so ) was calculated by regression analysis using the means of the CPE ratings at each concentration of compound.
Morphological changes from compound cytotoxicity were graded on a scale of 0-5; 5 being defined as complete 
Virus yield assay
As a follow-up to the CPE inhibition and NR uptake assays, virus yields from a second CPE inhibition assay were determined for each active compound (SI>10). Mter CPE was scored as described above, each plate was frozen at -80°C and thawed. Samples wells at each compound concentration tested were pooled and titrated for infec-tious virus. Titration was accomplished by using a 10-fold dilution series in medium without serum. Each dilution was plated in triplicate on monolayers of susceptible cells. After absorption (1 h) the sample was removed, maintenance medium added and the plates incubated at 3TC until the virus control wells showed 4+ CPE. Because a 50% reduction of virus titre represents relatively weak antiviral activity, a 90% reduction in virus yield was calculated by regression analysis. This represented a 1 10giO inhibition in titre when compared to untreated virus controls. An SI was calculated by the formula SI=CCsiEC9o' The CC so was from a cell yield assay of log phase cells exposed to compound.
Cell yield assay
Cytotoxicity in rapidly dividing cells was evaluated by determining the total number of cells after a 3 day exposure to several concentrations of compound. Twelve-well tissue culture plates were seeded with 5x10 4 cells suspended in growth medium. After 4 h incubation at 3TC, the cells were approximately 20% confluent; the medium was replaced with growth medium containing the same concentrations of test compound as in the antiviral experiments. The cells were then incubated at 3TC for 72 h, at which time the medium was removed and the cells washed twice. Trypsin (0.25%) was added to each well and the cells incubated until they rounded and began to come off the plates. The medium containing trypsinized cells from each well was then subjected to vigorous trituration by pipette to provide a uniform cell suspension. From each suspension, 0.2 mL were added to 9.8 mL ofIsoton III (Coulter), an bHPMPA synthesized by Gilead Sciences (Foster City, Calif., USA) and received coded.
CHighest concentration tested.
dComplete cytotoxicity was observed at concentrations greater than shown. isotonic saline solution. Three samples from each cell suspension were then counted using a Coulter cell counter (Model Zb-l). CC so was then determined by regression analysis using percentages of control for each drug dilution lying within the linear portion of the regression line.
Results

Chemistry
The synthesis of compounds ( Fig. 1) 1, 2, Kim et al. (1990 Kim et al. ( , 1991a , except to derive 10 the diaminopurine sodium salt was used to alkylate the diethyl chloromethoxy-methoxymethyl phosphonate. The synthesis of phosphonates 12, 13, 14, 15 and 16 is shown in Fig. 2 (1991b) and 20 by Kim et al. (1992) .
Activity against influenza virus and RSV
Compound 13 was slighdy inhibitory to two influenza A viruses (HIN1; EC so 190, cc., >200, HIN3; EC so 24, CC so >100) and influenza B virus (EC so 22, CC so >100).
The EC so values for the other compounds were generally >500 Ilg mL-l (data not shown). Compound 19 did not inhibit RSV strains A2, Long, 18537 or bovine RSV by CPE inhibition and NR assays, although it did inhibit strain Utah 89 by CPE inhibition and virus yield reduction assays.
Activity against PIV-3
Two compounds, 3 and 11 had activity (S1> 10) against PIV-3 with EC so values of 5 and 3 Ilg ml.." and Sl of 52 and >333 in the NR assay (Table 1) . However, when 11 was further evaluated in a virus yield reduction assay the EC gO was> 100 and CC so was 30 (determined in actively growing cells). The anti-Pl.V activity of3 was verified by a virus yield reduction assay,giving an EC gO of 17 Ilg mL-l (ribavirin 4 Ilg mL-l). Compounds 3 and 11 were only slighdy inhibitory for two clinical isolates and the bovine 
Activity against Ad
Three compounds inhibited AdS by CPE inhibition and NR uptake assay (Table 1) . Compounds 4, 5 and 17 were found to be inhibitory with SI greater than 10; 17 was the most selective, although a small degree of virus CPE was detected at all drug concentrations. The compounds were inhibitory to other Ad strains evaluated (Table 3) . All strains were very sensitive to inhibition by compound 4, especially when evaluated in the virus yield reduction assay.
Compound 17 was the most selective inhibitor, being the least toxic. However, it was the least potent inhibitor of the other virus strains when results from virus yield reduction assays were compared. Compounds 4 and 5 were the most potent inhibitors of all virus strains as determined in all assays. However, compound 4 was the most toxic.The variability of the toxicity values shown in Table 3 was significantly influenced by the duration of the antiviral assay. For example, the assay for strain Trim took 8 days for full CPE development to occur in the untreated virus control wells as opposed to 5 days for the adenoid 75 strain. 230 Activity against MV One compound, 3, was inhibitory to MV (CC) with SI from 8 to 30 in the CPE inhibition, NR uptake and virus yield reduction assays (Table 1) . By virus yield reduction assay, the EC 90 was 12 /J.g mL-l (ribavirin 15 /J.g mL-1 ) . The compound was also tested against different MV strains (Table 4 ). It potently inhibited strains Halonen (EC so <0.03 to 0.07 /J.g mL-l) and Chicago (EC so <0.03 to 0.07 /J.g mL-l) but was much less inhibitory to the Edmonston strain. All MV strains were comparably inhibited by ribavirin, although strain Halonen appeared to be at least 10fold more sensitive to inhibition by this known active drug.
Discussion
We have described the synthesis and in vitro anti-respiratory virus activity of 20 acyclic phosphonomethylether nuc1eosides. A number of these compounds have been evaluated previously against DNA viruses and retroviruses and found to possess antiviral activity. Particularly, 1, 3, 6
and 17 have potent anti-retroviral activity (Holy, 1993; Balzarini et al., 1994) ; 4 and 5 have anti-DNA virus activity (Holy, 1993) . Compound 11 showed some PIV inhibitory activity with SI of 30 to >333 by CPE inhibition assay, but failed to inhibit virus in a virus yield assay.The compound also inhibited other strains and clinical isolates of PIV, but only weakly. Microscopic observation of infected cells revealed discernible CPE at all concentrations of compound that were evaluated, although the CPE was much less than observed in the virus cell controls suggesting that a sublethal infection occurred in the presence of even high concentrations of compound. PMEG (3) inhibited all MV strains except for the Edmonston laboratory strain. Evidently, the target inhibited by PMEG in the replication cycle of the other MV strains was not significant / for replication in the Edmonston strain infection. Genetic variability in the genes coding for some of the proteins (i.e. proteins Nand L, perhaps matrix protein, non-structural proteins) responsible for virus replication and its regulation (Griffin & Bellini, 1996) may account for this lack of inhibition. Such variability has been described for the nucleoprotein , matrix GS Rota etal, 1994) , and F and H glycoprotein genes (Rota et al., 1992) by analysis of the nucleotide sequences of the complimentary DNAs. If the genetic variability of the glycoprotein genes between current wild-type isolates, such as Chicago/1, and the vaccine strains ofMV (PA is just slightly indicative of the potential genetic variability of other MV genes, then these results are not unexpected. Rota et al. (1992) have suggested that there is a significant linear pattern of evolutionary change in MV glycoproteins in virus strains isolated in 1988-1989 when compared to wild-types isolated in 1977 and 1983 or earlier isolated virus strains (i.e. Edmonston).
Three compounds, 4, 5 and 17, inhibited most Ad strains evaluated. Compounds 4 (HPMPA) and 5 (HPMPC) were previously shown to possess anti-Ad Antiviral Chemistry & Chemotherapy 8 (3) activity (Gordon et al., 1991; Baba et al., 1987) , with EC so values ranging from 0.017-17 flg mL-1 for HPMPC (plaque reduction assay) and 0.04-2.5 flg mL-1 for HPMPA (CPE inhibition and plaque reduction assays). Our data are in general agreement with the results of those studies, although the compounds in our hands showed some strain-specific inhibition. This could be because ocular isolates, not respiratory isolates, were used in the study by Gordon et al. (1991) . Compound 17, a new compound, inhibited Ad, although it did not inhibit another type 5 laboratory strain. Microscopic observation of cells infected with certain strains of Ad (i.e. Ad5, both strains and Chicago/1) and treated with compound 17 revealed discernible CPE at all concentrations of compound that were evaluated, although the CPE was much less than observed in the virus cell controls, suggesting that virus toxicity was not completely inhibited at any concentration tested.
The mode of inhibition by these compounds (i.e. 3) of PIV-3 and MV is unknown. It could involve virus RNA polymerases or some other aspect of viral transcription. Several aspects of gene structure and virus replication are common to both MV and PIV-3 viruses. They have highly conserved GAA or GGG sequences between each gene and depend on pseudo-templated transcription (RNA editing), which involves cotranscriptional insertion of G residues into the nascent P (phosphoprotein that forms part of the viral polymerase complex) gene mRNA by stuttering of the viral polymerase at a specific site in the template (Collins et al., 1996) . Since PMEG is phosphorylated by guanylate kinase (Ho et al., 1992) and inhibits purine nucleoside phosphorylase, an enzyme involved in the guanine salvage pathway (Holy et al., 1990) , perhaps PMEG perturbs guanine metabolism to interfere with RNA editing. Significantly, RSV does not share this commonalty with MV and PIV-3 and was not inhibited by PMEG.
Anti-Ad activity could involve inhibition ofviral DNA polymerases, as has been shown with HSV-1 (Holy et al, 1990) , inhibition of the processivity of the Ad-mediated DNA polymerization reaction enhanced by Ad DNA binding protein, as has been postulated with HPMPA (Mul et al., 1989) , or inhibition of key cellular target proteins necessary for viral replication.
In summary, we have identified promising lead compounds with inhibitory activity in vitro against PIV-3, MV and Ad. The true potential of these compounds will be further addressed by more in vitro testing, evaluation in animal models and by exploring their mechanism of action.
